Navigation Links
Aethlon Medical Releases Shareholder Letter

SAN DIEGO, July 14, 2011 /PRNewswire/ -- Aethlon Medical, Inc., (OTCBB: AEMD) disclosed today that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders.


To our Shareholders:

Last December, I authored a shareholder letter which referenced the viewpoint of healthcare leaders who felt a need for innovative new therapeutic strategies to evolve as escalating regulatory costs, challenges and uncertainties made it nearly impossible for small to mid-size organizations to commercialize their drug candidates.  In response, we introduced the Aethlon ADAPT™ (Adaptive Dialysis-Like Affinity Platform Technology) system, as an innovative medical device platform that provides a basis to create new therapeutic devices through the convergence of affinity drug agents and plasma membrane technologies.  The Aethlon ADAPT™ system provides a previously unrecognized commercialization pathway to antibody and other affinity drug developers, who should also appreciate a less onerous medical device regulatory pathway.  We are already seeing evidence of our ADAPT™ system being the impetus for industry collaborations that offer new channels of early revenue generation.  

On May 25th, we introduced our Aethlon ADAPT™ system to the drug industry at the C21 Life Sciences Partnering Conference.  However, we had already begun to leverage our ADAPT™ system on April 1st, through a response to a government contract opportunity offered by the Defense Advanced Research Projects Agency (DARPA) entitled, "Dialysis-Like Therapeutics."  Included within our response was a proposal to develop a device that would reduce the incidence of sepsis in wounded war-fighters.  I am pleased to inform you that our submitted program was chosen for funding by a panel of experts assembled by DARPA.  While it is an honor to be chosen to receive a contract award, I ask that you curb any assumption that we have won a contract based on information that may be published on the Internet.  A contract that leads to funding of our proposed program is predicated on the successful completion of a detailed contracting process.  On June 29th, we again leveraged the capabilities of our ADAPT™ system through a response to a U.S. Army initiative to create a device that would meet the objective of a program entitled "Blood Purification for Organ Failure."  

The genesis of the Aethlon ADAPT™ system is our Hemopurifier®, a device that has demonstrated broad-spectrum activity against infectious viral pathogens, immunosuppressive proteins and exosomes secreted by cancer.  Increasingly, exosomes are being discovered to have implications in other life-threatening diseases.  Next Tuesday (July 19th), we will meet with FDA officials to discuss a proposed clinical program to support the regulatory advancement of our Hemopurifier® as a treatment countermeasure against bioterror and pandemic threats.  Based on data collected from clinical programs conducted in India, we will also seek permission from the FDA to expand our treatment indications to include Hepatitis C virus (HCV).  Formal FDA feedback to next week's meeting would likely occur in early fall.  Should the FDA grant permission to initiate our U.S. clinical studies, we have already submitted (on May 31st of this year) a request to the Biomedical Advanced Research and Development Authority (BARDA) to fund clinical programs specific to bioterror and pandemic threats.  In the meantime, we continue to advance our HCV treatment program at the Medanta Medicity Institute.  As previously communicated, positive clinical outcomes from this study will lead to commercialization of our Hemopurifier® in India.  Regardless of the many challenges we have confronted, we continue to advance our mission to create innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.  On behalf of your dedicated team at Aethlon Medical, I again thank you for your continued support and belief in our endeavors.

Very truly yours,

James A. Joyce
Chairman, CEO

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT system including consummating government contracts or grants, the FDA's willingness to allow the Company to proceed with the clinical trials proposed in the re-initiation of an Investigational Device Exemption (IDE) study, or the FDA's willingness to meet with company officials to discuss Emergency Use Authorization (EUA) for the Hemopurifier® as a broad-spectrum countermeasure against untreatable viral threats, the Company's ability to conduct clinical trials in Europe or to achieve regulatory approval in Europe, the Company's ability to commercialize its Hemopurifier® in India, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.


James A. Joyce
Chairman and CEO
858.459.7800 x301

Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates

Jim Frakes
Chief Financial Officer
858.459.7800 x300

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
(Date:10/8/2015)... Oct. 9, 2015 Johnson & Johnson (NYSE: ... immunogenicity clinical trial in Sierra Leone ... Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first ... first study conducted of Janssen,s Ebola prime-boost vaccine regimen in ... Sierra Leone,s Kambia district, where ...
(Date:10/8/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a ... diseases, today announced that clinical data for the ... at the 2015 American College of Gastroenterology (ACG) ... sustained response in IBS-C patients enrolled in the ... trial. The meeting will be held in ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... cell-free molecular diagnostics, today announced the presentation of ... use of its Precision Cancer Monitoring SM ... can be critical for physicians to determine appropriate ... chief scientific officer of Trovagene is delivering the ...
Breaking Medicine Technology:
... February is American Heart Month and a time when ... on their family history of heart disease and recommit ... teaming up with the makers of Bayer® Aspirin and ... to raise $100,000 for the fight against heart disease. ...
... 2012 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Leerink Swann 2012 Global Healthcare Conference to be ... New York City.  Mr. Adrian Adams, Chief Executive Officer ... the Company and its product pipeline at 10:30 a.m. ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern ... to be recognized by The National Law Journal for inclusion in their second ... firms across the United States who obtained the largest awards for their personal ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack from ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. This pack comes with 60 vibrant CUBE LUT files. , Inspired ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, ... risk of dying in reported home fires in half. As part of Fire Prevention ... are property installed and maintained. , Half of home fire deaths result from fires ...
(Date:10/9/2015)... ... , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend the ... in Huntsville, Texas on October 17-21. , "It's very exciting to be invited ... executive director, said. “It's a stepping stone into the U.S. elite system where Maddie ...
Breaking Medicine News(10 mins):
... Neuroscientists at MIT,s Picower Institute of Learning and Memory have ... inexplicably linked to long-term memories. The work is slated to ... "Our finding explains, at least partially, why seemingly irrelevant ... person is remembered as vividly as more significant information such ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay News) -- This winter ... instead is turning out to be a more typical flu season, ... to get a flu shot, advice that seniors in particular should ... their age group the hardest, the experts added. The H1N1 flu ...
... for Injury Biomechanics ( ) has been awarded ... Research and Materiel Command for phase 2 of an ... military personnel. Specifically, blast induced brain trauma will be ... helmet design and body armor and the resulting reductions ...
... Liverpool-led consortium has received $1.5million from the Bill & ... serious disease and epidemics in sub-Saharan Africa. Streptococcus ... in sub-Sahara Africa. The funding will enable scientists ... associated with invasive pneumococcal disease, why it spreads so ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay ... by patients and health professionals alike to save money ... and potentially dangerous, a new study suggests. Belgian ... deviated from recommended dosages by 15 percent or more. ...
... HealthDay Reporter , WEDNESDAY, Jan. 12 (HealthDay News) -- ... said Tuesday, breathing on her own and moving both arms ... "She has a 101 percent chance of surviving," Dr. ... told the Associated Press . "She will not die." ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: